WinSanTor, with a valuation cap of $75 million, is raising funds on StartEngine. The company is focused on developing drugs for the treatment of diabetic peripheral neuropathy. The first drug of WinSanTor is in the clinical trial and is expected to reach the patients in the next three years. The class of drugs discovered by WinSanTor scientists increases ATP production in the affected nerves and increases their growth. WinSanTor was founded by Paul Fernyhough, Nigel Calcutt, and Lakshmi Kotra and has already received over $25 million in peer-reviewed grants. The current round of crowdfunding has a minimum goal of $10,000 and a maximum goal of $535,000, and the funds will be used to complete the Phase 2 trials and prepare for the Phase 3 clinical trials. WinSanTor is bringing about a breakthrough in science, and its drugs could be the only disease-modifying treatment for any form of peripheral neuropathy.